Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors

Bryan, Marian C.; Whittington, Douglas A.; Doherty, Elizabeth M.; Falsey, James R.; Cheng, Alan C.; Emkey, Renee; Brake, Rachael L.; Lewis, Richard T.

doi:10.1021/jm201565s

Title: Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors

Full Record
Other Related Research

Authors:: Bryan, Marian C.; Whittington, Douglas A.; Doherty, Elizabeth M.; Falsey, James R.; Cheng, Alan C.; Emkey, Renee; Brake, Rachael L.; Lewis, Richard T.

Publication Date:: Thu Feb 23 00:00:00 EST 2012

Research Org.:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Org.:: INDUSTRY

OSTI Identifier:: 1259886

Resource Type:: Journal Article

Journal Name:: Journal of Medicinal Chemistry

Additional Journal Information:: Journal Volume: 55; Journal Issue: 4; Journal ID: ISSN 0022-2623

Publisher:: American Chemical Society (ACS)

Country of Publication:: United States

Language:: ENGLISH

Citation Formats


                    Bryan, Marian C., Whittington, Douglas A., Doherty, Elizabeth M., Falsey, James R., Cheng, Alan C., Emkey, Renee, Brake, Rachael L., and Lewis, Richard T. Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors.  United States: N. p., 2012. 
        Web.  doi:10.1021/jm201565s.

Copy to clipboard


                    Bryan, Marian C., Whittington, Douglas A., Doherty, Elizabeth M., Falsey, James R., Cheng, Alan C., Emkey, Renee, Brake, Rachael L., & Lewis, Richard T. Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors.  United States.  https://doi.org/10.1021/jm201565s

Copy to clipboard


                    Bryan, Marian C., Whittington, Douglas A., Doherty, Elizabeth M., Falsey, James R., Cheng, Alan C., Emkey, Renee, Brake, Rachael L., and Lewis, Richard T. 2012.  
        "Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors".  United States.  https://doi.org/10.1021/jm201565s.

Copy to clipboard


                    
@article{osti_1259886,

  title        = {Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors},

  author       = {Bryan, Marian C. and Whittington, Douglas A. and Doherty, Elizabeth M. and Falsey, James R. and Cheng, Alan C. and Emkey, Renee and Brake, Rachael L. and Lewis, Richard T.},

  abstractNote = {},

  doi          = {10.1021/jm201565s},

  url          = {https://www.osti.gov/biblio/1259886},
  journal      = {Journal of Medicinal Chemistry},

  issn         = {0022-2623},

  number       = 4,

  volume       = 55,

  place        = {United States},

  year         = {Thu Feb 23 00:00:00 EST 2012},

  month        = {Thu Feb 23 00:00:00 EST 2012}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1021/jm201565s

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

Journal Article Cui, J; Tran-Dube, ; Michelle, ; ... - Journal of Medicinal Chemistry

Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with amore »« less
https://doi.org/10.1021/jm2007613
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer

Journal Article Lewis, Richard; Bode, Christiane; Choquette, Deborah; ... - J. Med. Chem.
https://doi.org/10.1021/jm3005866
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer

Journal Article Lewis, Richard; Bode, Christiane; Choquette, Deborah; ... - Journal of Medicinal Chemistry
https://doi.org/10.1021/jm3005866
Discovery of Potent, Selective, and Brain-Penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors

Journal Article Fushimi, M; Fujimori, I.; Wakabayashi, T.; ... - Journal of Medicinal Chemistry
https://doi.org/10.1021/acs.jmedchem.8b01630
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib

Journal Article Huang, Qinhua; Johnson, Ted; Bailey, Simon; ... - Journal of Medicinal Chemistry

Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
https://doi.org/10.1021/jm401805h

Similar Records